DNTH vs IONS: stock comparison and AI forecast
Dianthus Therapeutics, Inc. /De/ (DNTH) and Ionis Pharmaceuticals Inc (IONS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DNTH Dianthus Therapeutics, Inc. /De/
- Price
- $88.81 +3.1% · 6M
- Market Cap
- $4.97B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
IONS Ionis Pharmaceuticals Inc
- Price
- $31.00 -58.9% · 6M
- Market Cap
- $5.15B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- DNTH and IONS have similar market capitalizations ($4.97B and $5.15B).
- Over the last six months DNTH returned +3.1% and IONS -58.9%.
- IONS turns -155.6% of its revenue into net income, against -17469.7% for DNTH.
- IONS carries 6.40 times debt per unit of equity, against 0.03 times for DNTH.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DNTH | IONS |
|---|---|---|
| Market Cap | $4.97B | $5.15B |
| P/B Ratio | 4.00x | 13.09x |
| EPS | $-4.06 | $-2.93 |
| Book Value/Share | $22.19 | $2.37 |
| Revenue/Share | – | $2.11 |
| FCF/Share | – | $-3.71 |
Profitability & Margins
| Metric | DNTH | IONS |
|---|---|---|
| ROE | -16.3% | -138.8% |
| ROA | -15.8% | -18.8% |
| ROIC | -18.9% | -22.8% |
| Gross Margin | – | 95.2% |
| Operating Margin | -20400.0% | -160.8% |
| Net Margin | -17469.7% | -155.6% |
| EBT Margin | -20400.0% | -154.8% |
| Tax Rate | – | -0.5% |
Financial Health
| Metric | DNTH | IONS |
|---|---|---|
| Current Ratio | 30.02x | 5.43x |
| Quick Ratio | – | 5.36x |
| D/E Ratio | 0.03x | 6.40x |
| Financial Leverage | 1.03x | 7.40x |
| Interest Coverage | – | -28.2x |
| Working Capital | $828M | $1.93B |
Cash Flow
| Metric | DNTH | IONS |
|---|---|---|
| Operating Cash Flow | -$175M | -$544M |
| Free Cash Flow | – | -$616M |
| Capital Spending | – | -$72M |
| FCF/Sales | – | -175.4% |
| CapEx/Sales | – | 20.4% |
Operational Efficiency
| Metric | DNTH | IONS |
|---|---|---|
| Asset Turnover | – | 0.12x |
| Inventory Turnover | – | 0.6x |
| Fixed Assets Turnover | – | 2.2x |
| Days Inventory | – | 614 days |
| Payables Period | – | 582 days |
Income Statement
| Metric | DNTH | IONS |
|---|---|---|
| Total Revenue | – | $351M |
| Operating Income | -$236M | -$565M |
| Net Income | -$202M | -$547M |
| R&D Expense | $189M | – |
| SG&A Expense | – | $585M |
| Cost of Goods Sold | – | $17M |
Dividend & Shareholder Information
| Metric | DNTH | IONS |
|---|---|---|
| Shares Outstanding | 56M | 166M |
DNTH vs IONS: stock comparison and AI forecast
Which is bigger, DNTH or IONS?
DNTH and IONS have similar market capitalizations ($4.97B and $5.15B).
Which stock performed better over the last six months, DNTH or IONS?
Over the last six months DNTH returned +3.1% and IONS -58.9%.
Which one does Intratio's AI model rank higher, DNTH or IONS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.